The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 8, 2012, Pages 958-964

  Gao, Xiang ^a   Zhang, Fang Bin ^a   Ding, Liang ^a   Liu, Hui ^a   Wang, Xue Ding ^a   Chen, Bai Li ^a   Bi, Hui Chang ^a   Xiao, Ying Lian ^a   Zhao, Li Zi ^a   Chen, Min Hu ^a   Huang, Min ^a   Hu, Pin Jin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

5 aminosalicylic acid; myelotoxicity; thiopurines

Indexed keywords

AZATHIOPRINE; ETIASA; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CHILD; ENTERITIS; FEMALE; FLU LIKE SYNDROME; HUMAN; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASIAN CONTINENTAL ANCESTRY GROUP; AZATHIOPRINE; BONE MARROW; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; METHYLTRANSFERASES; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; THIONUCLEOTIDES; YOUNG ADULT;

EID: 84864069451     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283545ae3     Document Type: Article

References (23)

1. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 331-342.
2. Krynetskaia NF, Krynetski EY, Evans WE. Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol Pharmacol 1999; 56:841-848.
3. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111-113.
4. Sandborn WJ. Azathioprine: State of the art in inflammatory bowel disease. Scand J Gastroenterol 1998; 225:92.
5. Jharap B, Seinen ML, De Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, et al. Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16:1541-1549.
6. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Pharmacol 1983; 16:359-363.
7. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20:1149.
8. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91:423-433.
9. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025-1030.
10. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003; 3:CD000543.
11. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002; 4:CD000544.
12. Hanauer SB. Aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20:60-65.
13. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: Aromatic thiol substrates and inhibition by benzoic acid. Mol Pharmacol 1983; 24:471-478.
14. Lowry PW, Szumlanski CL, Weinsiboum RM, Szumlanski CL, Mays DC, Loftus EV, et al. Balsalazide and azathioprine or 6-mercaptopurine: Evidence for a potentially serious drug interaction. Astroenterology 1999; 116: 1505-1506.
15. Lowry PW, Franklin CL, Weaver AL, Sandborn WJ. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulfasalazine, or balsalazide. Gut 2001; 49: 656-664.
16. Dewit O, Vanderheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: An in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16:79-85.
17. Zheng JJ, Zhu Q, Shi X. Efficacy and safety of azathioprine maintenance therapy in a group of patients with Crohn's disease in East China. Chinese J Digest 2007; 27:299-302.
18. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170:2-6.
19. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A):5-36.
20. Zhang JP, Guan YY, Wu JH, Xu AL, Zhou S, Huang M. Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: A comparison of Han and Yao ethnic groups. Br J Clin Pharmacol 2004; 58:163-168.
21. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998; 44:551-555.
22. Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 008; 28:973-983.
23. Ding L, Zhang FB, Liu H, Gao X, Bi HC, Wang XD, et al. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2011; 18:63-73.